Invest in 5,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. more
Time Frame | DNA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.71% | 1.89% | -0.81% |
1-Month Return | -20.14% | -2.71% | -3.95% |
3-Month Return | -31.46% | 1.31% | 3.35% |
6-Month Return | -41.58% | 11.93% | 19.7% |
1-Year Return | -31.46% | 6.35% | 22.93% |
3-Year Return | -91.61% | 19.71% | 25.5% |
5-Year Return | -91.4% | 76.38% | 85.41% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 54.18M | 76.66M | 313.84M | 477.71M | 251.46M | [{"date":"2019-12-31","value":11.34,"profit":true},{"date":"2020-12-31","value":16.05,"profit":true},{"date":"2021-12-31","value":65.7,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":52.64,"profit":true}] |
Cost of Revenue | - | 15.61M | 129.69M | 204.22M | 108.81M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":7.64,"profit":true},{"date":"2021-12-31","value":63.51,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":53.28,"profit":true}] |
Gross Profit | 54.18M | 61.05M | 184.15M | 273.49M | 142.64M | [{"date":"2019-12-31","value":19.81,"profit":true},{"date":"2020-12-31","value":22.32,"profit":true},{"date":"2021-12-31","value":67.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":52.16,"profit":true}] |
Gross Margin | 100.00% | 79.64% | 58.68% | 57.25% | 56.73% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":79.64,"profit":true},{"date":"2021-12-31","value":58.68,"profit":true},{"date":"2022-12-31","value":57.25,"profit":true},{"date":"2023-12-31","value":56.73,"profit":true}] |
Operating Expenses | 125.78M | 198.07M | 2.01B | 2.48B | 814.87M | [{"date":"2019-12-31","value":5.07,"profit":true},{"date":"2020-12-31","value":7.98,"profit":true},{"date":"2021-12-31","value":81.07,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":32.83,"profit":true}] |
Operating Income | (71.60M) | (137.03M) | (1.83B) | (2.21B) | (672.23M) | [{"date":"2019-12-31","value":-7159800000,"profit":false},{"date":"2020-12-31","value":-13702700000,"profit":false},{"date":"2021-12-31","value":-182846700000,"profit":false},{"date":"2022-12-31","value":-220895200000,"profit":false},{"date":"2023-12-31","value":-67223100000,"profit":false}] |
Total Non-Operating Income/Expense | (44.90M) | 12.39M | (11.19M) | 107.71M | (165.46M) | [{"date":"2019-12-31","value":-41.69,"profit":false},{"date":"2020-12-31","value":11.5,"profit":true},{"date":"2021-12-31","value":-10.39,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-153.62,"profit":false}] |
Pre-Tax Income | (119.83M) | (124.83M) | (1.84B) | (2.12B) | (892.94M) | [{"date":"2019-12-31","value":-11983500000,"profit":false},{"date":"2020-12-31","value":-12483400000,"profit":false},{"date":"2021-12-31","value":-183812200000,"profit":false},{"date":"2022-12-31","value":-212139900000,"profit":false},{"date":"2023-12-31","value":-89294000000,"profit":false}] |
Income Taxes | 22.00K | 1.89M | (1.48M) | (15.03M) | (71.00K) | [{"date":"2019-12-31","value":1.16,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-78.35,"profit":false},{"date":"2022-12-31","value":-795.5,"profit":false},{"date":"2023-12-31","value":-3.76,"profit":false}] |
Income After Taxes | (119.86M) | (126.72M) | (1.84B) | (2.11B) | (892.87M) | [{"date":"2019-12-31","value":-11985700000,"profit":false},{"date":"2020-12-31","value":-12672300000,"profit":false},{"date":"2021-12-31","value":-183664200000,"profit":false},{"date":"2022-12-31","value":-210637200000,"profit":false},{"date":"2023-12-31","value":-89286900000,"profit":false}] |
Income From Continuous Operations | (119.86M) | (126.72M) | (1.84B) | (2.11B) | (854.25M) | [{"date":"2019-12-31","value":-11985700000,"profit":false},{"date":"2020-12-31","value":-12672300000,"profit":false},{"date":"2021-12-31","value":-183664200000,"profit":false},{"date":"2022-12-31","value":-210637200000,"profit":false},{"date":"2023-12-31","value":-85425300000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (119.86M) | (126.72M) | (1.84B) | (2.11B) | (892.87M) | [{"date":"2019-12-31","value":-11985700000,"profit":false},{"date":"2020-12-31","value":-12672300000,"profit":false},{"date":"2021-12-31","value":-183664200000,"profit":false},{"date":"2022-12-31","value":-210637200000,"profit":false},{"date":"2023-12-31","value":-89286900000,"profit":false}] |
EPS (Diluted) | - | - | (1.52) | (1.23) | (0.47) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-152,"profit":false},{"date":"2022-12-31","value":-123,"profit":false},{"date":"2023-12-31","value":-47,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
DNA | |
---|---|
Cash Ratio | 5.79 |
Current Ratio | 6.11 |
Quick Ratio | 6.11 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
DNA | |
---|---|
ROA (LTM) | -21.82% |
ROE (LTM) | -63.02% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
DNA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.34 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.66 |
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. | 1.52 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
DNA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 8.65 |
P/B | 1.98 |
Price/FCF | NM |
EV/R | 5.85 |
EV/Ebitda | NM |
PEG | NM |
IGDI will leverage Ginkgo''s Adaptive Laboratory Evolution technology to improve its sourdough starter culture product PADUA, Italy and BOSTON, April 16, 2024 /PRNewswire/ -- Il Granaio delle Idee (IGDI), an innovative international developer and provider of clean label baking ingredients,…
Il Granaio delle Idee and Ginkgo Bioworks collaborate to enhance sourdough strains for bakery products using ALE technology. IGDI''s Pater product aims to improve flavor, aroma, and shelf life of baked goods, with Ginkgo''s support. The partnership seeks to innovate and optimize sourdough production for artisanal and industrial bakers.
The collaboration could help solve challenges for both businesses.
BOSTON, April 11, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of AgBiome''s platform assets, including over 115,000 fully sequenced and isolated strains, over 500 million…
Ginkgo Bioworks (NYSE: DNA) acquires AgBiome''s platform assets, including over 115,000 fully sequenced strains and 500 million gene sequences, enhancing Ginkgo''s ag biological discovery platform. AgBiome''s validated product concepts offer a strong foundation for future developments.
WASHINGTON (dpa-AFX) - Ginkgo Bioworks (DNA) announced the expansion of its strategic partnership with Novo Nordisk under a framework agreement that initially is contemplated to run over five year…
Ginkgo Bioworks Holdings (DNA) share price today is $0.8705
Yes, Indians can buy shares of Ginkgo Bioworks Holdings (DNA) on Vested. To buy Ginkgo Bioworks Holdings from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in DNA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Ginkgo Bioworks Holdings (DNA) via the Vested app. You can start investing in Ginkgo Bioworks Holdings (DNA) with a minimum investment of $1.
You can invest in shares of Ginkgo Bioworks Holdings (DNA) via Vested in three simple steps:
The 52-week high price of Ginkgo Bioworks Holdings (DNA) is $2.54. The 52-week low price of Ginkgo Bioworks Holdings (DNA) is $0.81.
The price-to-earnings (P/E) ratio of Ginkgo Bioworks Holdings (DNA) is NM
The price-to-book (P/B) ratio of Ginkgo Bioworks Holdings (DNA) is 1.98
The dividend yield of Ginkgo Bioworks Holdings (DNA) is 0.00%
The market capitalization of Ginkgo Bioworks Holdings (DNA) is $1.44B
The stock symbol (or ticker) of Ginkgo Bioworks Holdings is DNA